May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Results From a Multi-Center, Randomized Clinical Trial Comparing Argon Laser and Titanium:Sapphire Laser Trabeculoplasty to Treat Primary Open Angle Glaucoma
Author Affiliations & Notes
  • P. J. Harasymowycz
    Ophthalmology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
    Montreal Glaucoma Institute, Montreal, Quebec, Canada
  • I. Ahmed
    Ophthalmology, Credit Valley Eye Care, Toronto, Ontario, Canada
  • B. Perez
    International Eye Center, Tampa, Florida
  • J. Bacharach
    North Bay Eye Associates, Petaluma, California
  • J. Garcia-Feijoo
    Ophthalmology, Hospital San Carlos, Spain, Madrid, Spain
  • S. Kurtz
    Ophthalmology, Sourasky Medical Center, Israel, Tel Aviv, Israel
  • S. Melamed
    Ophthalmology, Goldschleger Eye Institute, Israel, Tel Hashomer, Israel
  • Footnotes
    Commercial Relationships  P.J. Harasymowycz, Occulogix, C; Occulogix, R; I. Ahmed, Occulogix, C; Occulogix, R; B. Perez, Occulogix, C; Occulogix, R; J. Bacharach, Occulogix, C; Occulogix, R; J. Garcia-Feijoo, Occulogix, C; Occulogix, R; S. Kurtz, Occulogix, C; Occulogix, R; S. Melamed, Occulogix, C; Occulogix, R.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1232. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. J. Harasymowycz, I. Ahmed, B. Perez, J. Bacharach, J. Garcia-Feijoo, S. Kurtz, S. Melamed; Results From a Multi-Center, Randomized Clinical Trial Comparing Argon Laser and Titanium:Sapphire Laser Trabeculoplasty to Treat Primary Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1232. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare the clinical findings following laser trabeculoplasty using argon (ALT) and Titanium:Sapphire (TLT) lasers in eyes with primary open angle glaucoma (POAG).

Methods: : 167 eyes (83 ALT; 88 TLT) of 160 patients at least 18 years old with POAG and baseline intraocular pressure (IOP) ≥ 22mmHg; while failed either maximally tolerated glaucoma medication or previous laser trabeculoplasty were enrolled in the study. Demographics for the two groups were comparable in terms of age (ALT 67.4+12.9; TLT 67.1+11.0) and gender (ALT 61.0% female; TLT 62.7% female). Baseline IOP (ALT 24.8+3.4; TLT 25.4+3.4 mmHg) and number of glaucoma meds (ALT 1.7+0.9; TLT 1.6+1.0) were also comparable.Treatment consisted of 50 laser exposures over 180 degrees of trabecular meshwork for both the CW argon (488/514nm; 50-100um spot size; 50-100mW) and pulsed Titanium:Sapphire (790nm; 200um spot size; 30 to 80 mJ/pulse) lasers.

Results: : Primary endpoint for success was percent IOP reduction from baseline at follow-up visits of 1 week, and 1, 3, 6 and 12 months. All IOP were measured using a Goldmann tonometer. Percent IOP reduction was comparable at 6 months for ALT 23.9+17.2 % (n=60) and TLT 26.9+17.3 % (n=61) (p=0.34); and 12 months 20.2+17.3 % for ALT (n=45) and 26.8+16.2% for TLT (n=41) (p=0.07). Incidences of minor complications commonly associated with trabeculoplasty were infrequent and also comparable between the two groups.

Clinical Trial: : NCT00145535

Keywords: laser • clinical (human) or epidemiologic studies: outcomes/complications • trabecular meshwork 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.